Next Article in Journal
Diagnostic Performance of Host and Viral DNA Methylation Analysis in the Identification of Anal Intraepithelial Neoplasia and Cancer: Systematic Review and Meta-Analysis
Next Article in Special Issue
Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review
Previous Article in Journal
The Effects of the Expansion of Dental Care Coverage for the Elderly
Previous Article in Special Issue
Polish Adaptation and Psychometric Validation of the PREM-C9 Questionnaire for Patients with Chronic Obstructive Pulmonary Disease
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review

1
Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam
2
Faculty of Pharmacy, Le Van Thinh Hospital, Ho Chi Minh City 700000, Vietnam
*
Author to whom correspondence should be addressed.
Healthcare 2024, 12(19), 1950; https://doi.org/10.3390/healthcare12191950
Submission received: 8 August 2024 / Revised: 6 September 2024 / Accepted: 23 September 2024 / Published: 29 September 2024

Abstract

Objectives: Pneumococcal disease, caused by Streptococcus pneumoniae, is the leading cause of mortality in children worldwide. The tremendous direct cost of hospital admissions and significant indirect costs from productivity loss contribute considerably to its economic burden, with vaccination being the only efficient protection against the illness. Our study aims to summarize the cost-effectiveness of the pneumococcal conjugate vaccine (PCV) implemented in the pediatric population. Methods: Employing the online databases PubMed, Embase, and Medline, we looked for economic evaluations from 2018 until March 2024. The Incremental Cost-Effectiveness Ratios (ICER) and Quality-Adjusted Life Years (QALY) were the primary outcomes for measuring the cost-effectiveness of PCVs. A 28-item CHEERS 2022 checklist was applied to assess the quality of the collected studies. Results: Of the 16 papers found, 9/16 discussed the lower-valent vaccines (PCV13, PCV10) and 7/16 examined the higher-valent vaccines (PCV20, PCV15). PCV13 and PCV10 involved greater costs and generated more QALY compared to no vaccination. Both PCV15 and PCV20 averted substantial healthcare costs and yielded greater quality of life than PCV13. Additionally, PCV20 was a dominant strategy compared to PCV15. Conclusions: Utilizing PCV13 is a very cost-effective option compared to not getting vaccinated. Transitioning from PCV13 to PCV20 would result in higher QALY gain and more cost-saving than switching to PCV15.
Keywords: cost-effectiveness analysis; pneumococcal vaccine; pediatric; systematic review cost-effectiveness analysis; pneumococcal vaccine; pediatric; systematic review

Share and Cite

MDPI and ACS Style

Vo, N.X.; Pham, H.L.; Bui, U.M.; Ho, H.T.; Bui, T.T. Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review. Healthcare 2024, 12, 1950. https://doi.org/10.3390/healthcare12191950

AMA Style

Vo NX, Pham HL, Bui UM, Ho HT, Bui TT. Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review. Healthcare. 2024; 12(19):1950. https://doi.org/10.3390/healthcare12191950

Chicago/Turabian Style

Vo, Nam Xuan, Huong Lai Pham, Uyen My Bui, Han Tue Ho, and Tien Thuy Bui. 2024. "Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review" Healthcare 12, no. 19: 1950. https://doi.org/10.3390/healthcare12191950

APA Style

Vo, N. X., Pham, H. L., Bui, U. M., Ho, H. T., & Bui, T. T. (2024). Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review. Healthcare, 12(19), 1950. https://doi.org/10.3390/healthcare12191950

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop